Johnson & Johnson (JNJ) Shares Bought by Wealth Architects LLC

Wealth Architects LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,298 shares of the company’s stock after acquiring an additional 486 shares during the quarter. Wealth Architects LLC’s holdings in Johnson & Johnson were worth $819,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Landmark Financial Advisors LLC boosted its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after acquiring an additional 7 shares during the last quarter. Paradigm Financial Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.3% during the 2nd quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after buying an additional 9 shares in the last quarter. Premier Asset Management LLC raised its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after buying an additional 12 shares in the last quarter. Lbmc Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after buying an additional 14 shares in the last quarter. Finally, Halbert Hargrove Russell LLC raised its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 65.58% of the company’s stock.

Johnson & Johnson (NYSE JNJ) opened at $129.91 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 12 month low of $119.25 and a 12 month high of $148.32. The stock has a market capitalization of $351,584.88, a P/E ratio of 333.10, a PEG ratio of 2.19 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The firm had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same period in the previous year, the firm earned $1.58 earnings per share. The business’s revenue was up 11.5% compared to the same quarter last year. sell-side analysts anticipate that Johnson & Johnson will post 8.11 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.59%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 861.54%.

In other news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.19% of the stock is currently owned by insiders.

JNJ has been the topic of a number of research reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective on the stock in a report on Thursday, January 11th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, Stifel Nicolaus raised their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Four analysts have rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $146.16.

ILLEGAL ACTIVITY WARNING: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/22/johnson-johnson-jnj-shares-bought-by-wealth-architects-llc.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply